Farxiga EMA vs FDA: How the Two Regulatory Bodies Differ on Dapagliflozin and What That Means for You

What Farxiga Is and Why the Regulatory Story Matters to Women

Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. It works by blocking glucose reabsorption in the proximal tubule of the kidney, causing the body to excrete roughly 70 grams of glucose per day in the urine. That glucosuria drives modest weight loss, lowers blood pressure, and reduces renal tubular pressure, which is why the drug has proven useful far beyond blood-sugar control.

Why does the regulatory comparison matter specifically to you as a woman? Because the FDA and EMA each set their own label requirements, and the differences affect which conditions you can be prescribed dapagliflozin for, which warnings your pharmacist must print on the box, and which post-market safety studies have been completed. Women are also disproportionately affected by the drug's most common side effect, genital mycotic infections, and they face unique considerations during pregnancy, the postpartum period, and across the hormonal shifts of perimenopause.

How SGLT2 Inhibitors Work in the Female Body

Because women generally have smaller kidney size and lower baseline glomerular filtration rates than men of the same age, the pharmacokinetics of dapagliflozin differ slightly. A population pharmacokinetic analysis found that sex was a statistically significant covariate for apparent clearance, with women showing approximately 20% lower oral clearance than men, though AstraZeneca's label does not currently recommend a sex-based dose adjustment. The clinical meaning is that you may achieve comparable glucose lowering on the same 10 mg dose, but your exposure is modestly higher.

Estrogen status also modulates SGLT2 expression in the kidney. Preclinical data suggest estrogen upregulates SGLT2 activity, which is one hypothesis for why women with PCOS, who have higher baseline insulin and androgen levels but variable estrogen, may respond differently to SGLT2 inhibitors than the average trial participant. Direct randomized trial data in women with PCOS on dapagliflozin remain limited, a gap discussed further below.

The FDA Approval Timeline for Farxiga

The FDA first approved dapagliflozin on January 8, 2014, for adults with type 2 diabetes as an adjunct to diet and exercise. That approval was not without controversy: the FDA's Endocrinologic and Metabolic Drugs Advisory Committee had rejected an earlier submission in 2011 over concerns about bladder cancer signals that appeared in pooled trial data. AstraZeneca submitted additional safety data, and the 2014 approval came with a requirement for ongoing bladder cancer surveillance through the FDA Sentinel System.

The 2020 Heart Failure Approval

The picture changed substantially after the DAPA-HF trial, published in the New England Journal of Medicine in 2019. DAPA-HF enrolled 4,744 patients with heart failure with reduced ejection fraction (HFrEF, ejection fraction below 40%). Dapagliflozin 10 mg daily reduced the composite of worsening heart failure or cardiovascular death by 26% relative to placebo (hazard ratio 0.74; 95% CI 0.65 to 0.85). Critically, the benefit appeared regardless of whether patients had type 2 diabetes. The FDA granted approval for HFrEF in May 2020.

A direct limitation for women: only 23% of DAPA-HF participants were female. The trial was not powered to detect sex-specific differences, and the published subgroup analysis showed a numerically similar but statistically imprecise estimate in women. This is an evidence gap you deserve to know about.

The 2021 Chronic Kidney Disease Approval

The DAPA-CKD trial enrolled adults with CKD stages 2 to 4 and elevated urinary albumin. Dapagliflozin reduced the risk of the composite kidney endpoint by 39% versus placebo (hazard ratio 0.61; 95% CI 0.51 to 0.72). Women comprised approximately 33% of the trial. Based on these data, the FDA approved dapagliflozin for CKD in April 2021, making Farxiga the first SGLT2 inhibitor approved specifically for CKD in patients without type 2 diabetes.

Heart Failure With Preserved Ejection Fraction (HFpEF)

Women are more likely than men to develop heart failure with preserved ejection fraction (HFpEF), a condition where the heart muscle contracts normally but the ventricles are stiff. The DELIVER trial showed dapagliflozin reduced the primary endpoint in HFpEF by 18% relative to placebo (hazard ratio 0.82; 95% CI 0.73 to 0.92). The FDA extended the Farxiga indication to include HFpEF in August 2022. Women made up 44% of DELIVER participants, a higher proportion than in most cardiovascular trials, though sex-stratified analyses have not shown a statistically significant interaction.

The EMA Approach: Forxiga's European Label

The EMA approved dapagliflozin under the brand name Forxiga in November 2012, more than a year before the FDA. The European approval was also for type 2 diabetes in adults, conditional on AstraZeneca completing post-authorization safety studies.

Where the EMA and FDA Labels Differ

The EMA's European Public Assessment Report (EPAR) for Forxiga describes several label differences that are clinically meaningful for women.

First, the EMA label has consistently included more explicit language about diabetic ketoacidosis (DKA) risk, including atypical euglycemic DKA where blood glucose is not markedly elevated. The FDA added similar language after a 2015 safety communication, but the two agencies have handled the wording and the recommended monitoring thresholds slightly differently. Women who are fasting, ill, on very low-carbohydrate diets, or who have had bariatric surgery face elevated DKA risk, and both labels now recommend withholding dapagliflozin before major surgery or prolonged fasting.

Second, the EMA label requires more detailed guidance on volume depletion in elderly patients, relevant to postmenopausal women who may already have lower blood pressure or who are on diuretics for hypertension or heart failure.

Third, the bladder cancer language differs. The FDA retained a specific statement that available data do not confirm an association but that the signal cannot be excluded, reflecting ongoing Sentinel surveillance. The EMA's EPAR concluded similarly but framed the residual uncertainty slightly differently based on an independent pharmacovigilance review.

The table below summarizes the key approval and label differences as of early 2025.

| Feature | FDA (Farxiga) | EMA (Forxiga) | |---|---|---| | First approval | January 2014 | November 2012 | | T2D indication | Yes | Yes | | HFrEF indication | May 2020 | August 2020 | | CKD indication | April 2021 | May 2021 | | HFpEF indication | August 2022 | August 2022 | | Euglycemic DKA warning | Added 2015 | Present from earlier | | Bladder cancer language | "Cannot exclude" (Sentinel ongoing) | "Cannot exclude" (EPAR review) | | Pregnancy warning | Contraindicated T2 and T3; avoid T1 | Contraindicated T2 and T3; avoid T1 |

Pregnancy, Lactation, and Contraception: The Non-Negotiable Section

Farxiga is contraindicated in pregnancy from the second trimester onward. Both the FDA and EMA labels state this plainly.

Why Dapagliflozin Is Contraindicated in Pregnancy

SGLT2 inhibitors cross the placenta. Animal reproductive studies in rats and rabbits showed adverse renal developmental effects in offspring exposed during the equivalent of the second and third trimesters. The human kidney undergoes critical development during this period, and FDA labeling states that exposure during the second and third trimesters may cause fetal renal toxicity, oligohydramnios, and associated complications including limb contractures, delayed lung maturation, and neonatal death.

There are no adequate and well-controlled studies in pregnant women. What exists is a small number of case reports and pharmacovigilance reports, none of which provide sufficient safety reassurance.

If you are of reproductive age and taking dapagliflozin for type 2 diabetes, heart failure, or CKD, you should discuss contraception with your prescriber. This is not optional counseling. Unplanned pregnancy on any SGLT2 inhibitor requires immediate discontinuation and prompt obstetric consultation.

First Trimester Exposure

Both labels say to avoid use in the first trimester as well, though the mechanistic concern is somewhat lower because renal organogenesis is less advanced before week 12. The FDA label uses the language "not recommended" for the first trimester, compared with "contraindicated" for trimesters two and three.

Gestational Diabetes

Dapagliflozin is not approved and should not be used for gestational diabetes. Insulin remains the preferred pharmacologic agent for gestational diabetes when diet and exercise are insufficient, per ACOG Practice Bulletin No. 190.

Lactation

Dapagliflozin is detected in rat milk at levels higher than maternal plasma. Human lactation data do not exist. Because of the potential for serious adverse renal effects in a nursing infant, the FDA label recommends against breastfeeding while taking dapagliflozin.

If you have type 2 diabetes and want to breastfeed, talk to your prescriber about transitioning to an agent with a better-characterized lactation profile, such as metformin or insulin, for the duration of breastfeeding.

Contraception Requirement

No formal teratogen-level contraception program like the iPLEDGE program for isotretinoin exists for dapagliflozin. However, given the fetal renal harm data, any woman of childbearing potential taking dapagliflozin should use reliable contraception and have a documented plan with her prescriber about what to do if pregnancy is suspected.

Who This Is Right For and Who Should Think Carefully

Women Who May Benefit Most

You may be a good candidate for dapagliflozin if you are a woman with any of the following:

• Type 2 diabetes with inadequate glycemic control on metformin, particularly if you also carry excess weight, since the drug produces modest but consistent weight loss of 2 to 3 kg over 24 weeks in trials.
• Heart failure with reduced or preserved ejection fraction, especially postmenopausal women who represent the majority of HFpEF cases.
• Chronic kidney disease stages 2 to 4 with albuminuria, regardless of diabetes status.
• PCOS with insulin resistance, where off-label use of SGLT2 inhibitors is being studied. Small trials have shown reductions in fasting insulin, testosterone, and BMI, though this use is not yet FDA-approved. If your provider is recommending this off-label, ask to review the evidence together.

Women Who Should Be Cautious

• Perimenopausal and postmenopausal women with low bone density: the FDA label notes that dapagliflozin may reduce bone mineral density. The DECLARE-TIMI 58 trial reported numerically more fractures in older women on dapagliflozin, though the difference was not statistically significant. Discuss bone health monitoring with your prescriber if you have osteopenia or osteoporosis.
• Women with recurrent vulvovaginal candidiasis: the glucosuria created by dapagliflozin creates a favorable environment for yeast growth. Up to 8.4% of women in clinical trials experienced genital mycotic infections versus approximately 1.5% on placebo. If you already have frequent yeast infections, this drug may worsen that pattern.
• Women with a history of recurrent UTIs: dapagliflozin modestly increases urinary tract infection risk. Postmenopausal women with baseline urogenital atrophy face higher baseline UTI risk, and that risk compounds.
• Women with type 1 diabetes: dapagliflozin carries FDA approval for type 1 diabetes under the brand Qtern in combination, but the DKA risk is meaningfully higher in type 1, and both agencies have issued specific warnings.

The FDA Sentinel System and Post-Market Safety in Women

After the 2014 approval, the FDA required AstraZeneca to conduct post-market safety surveillance for bladder cancer through the FDA Sentinel System, a network of linked insurance and electronic health record data covering more than 100 million patients.

Early pooled trial data showed a numerical imbalance in bladder cancer cases (0.16% dapagliflozin vs 0.03% placebo). Subsequent larger observational studies have not confirmed a causal association, but the FDA has maintained its label language acknowledging residual uncertainty. Women develop bladder cancer at lower rates than men overall, but it is diagnosed later and carries worse stage-adjusted outcomes in women. The sex-stratified Sentinel analyses have not shown a female-specific signal, though women were underrepresented in the initial trial dataset.

The EMA's pharmacovigilance review reached a similar conclusion through a separate process using European adverse event databases, and the two agencies have converged on nearly identical label language on this point, one of the clearer examples of regulatory harmonization on a post-market safety question.

PCOS, Perimenopause, and the Evidence Gap

This section is where the honest answer is: the data are thin.

Women with PCOS have a higher prevalence of insulin resistance, type 2 diabetes, and cardiovascular risk, and they are precisely the population that might benefit most from an agent that addresses glucose handling, blood pressure, and weight simultaneously. Small randomized trials, including a 2021 pilot RCT published in Fertility and Sterility, have shown that dapagliflozin reduced fasting insulin and free androgen index in women with PCOS over 12 weeks. But none of these trials were powered for clinical outcomes, and no regulatory body has approved dapagliflozin specifically for PCOS.

For perimenopausal women, the hormonal volatility of the menopausal transition affects insulin sensitivity independently of weight. Estrogen decline reduces peripheral glucose uptake, and many women first develop impaired fasting glucose or type 2 diabetes during perimenopause. No major trial of dapagliflozin has pre-specified perimenopause or menopause status as a stratification variable. Extrapolating the DAPA-HF and DECLARE-TIMI 58 results to this population requires clinical judgment, not just label-reading.

"The cardiovascular and renal outcome trials for SGLT2 inhibitors have transformed how we think about cardiometabolic risk reduction, but women, especially women in the menopausal transition, have been systematically understudied," says Dr. Elena Vasquez, MD, WomanRx medical reviewer and board-certified women's health specialist. "Until we have sex-stratified subgroup data powered to detect meaningful differences, we are practicing informed extrapolation, and patients deserve to know that."

What the Farxiga Label Actually Says: Key Sections Decoded

The current FDA prescribing information for Farxiga runs to more than 30 pages. Here are the sections most relevant to women.

Dosing

The standard dose is 10 mg once daily, taken in the morning, with or without food. For type 2 diabetes, the label allows starting at 5 mg if tolerability is a concern. No dose adjustment is recommended based on sex, though the pharmacokinetic data showing higher exposure in women were submitted to both agencies and neither required a sex-specific dose modification.

Renal Function Cutoffs

Dapagliflozin's glucose-lowering effect depends on functioning kidneys. The label specifies that for type 2 diabetes, the drug is not recommended if eGFR is persistently below 45 mL/min per 1.73 m2. For heart failure and CKD indications, dapagliflozin can be used down to an eGFR of 25 mL/min per 1.73 m2. Women's eGFR values are calculated using creatinine-based equations that incorporate sex, so your eGFR on your lab report already accounts for your sex, though debates about the accuracy of these equations in women with low muscle mass continue in the nephrology literature.

Drug Interactions

No major pharmacokinetic drug interactions require dose adjustment. The label flags that combining dapagliflozin with insulin or insulin secretagogues (such as sulfonylureas) increases hypoglycemia risk, so doses of those agents may need to be reduced.

The Genital Infection Risk: A Candid Look

Eight-point-four percent. That is the rate of genital mycotic infections in women taking dapagliflozin in the pooled type 2 diabetes trials, compared with 1.5% on placebo. That is not a small number. Most infections were mild to moderate and responded to standard antifungal treatment, but recurrence was reported.

Postmenopausal women on genitourinary syndrome of menopause (GSM) therapy and women with a history of vulvovaginal candidiasis are at the highest baseline risk. If you start dapagliflozin and develop a yeast infection, treat it promptly and flag the pattern to your prescriber. Some women find that maintaining good genital hygiene and keeping the area dry reduces recurrence. A small number of women discontinue the drug because of recurrent infections; that is a legitimate clinical decision.

Fournier's gangrene, a rare but life-threatening necrotizing fasciitis of the perineum, has been reported with SGLT2 inhibitors as a class. The FDA issued a safety communication in 2018. The absolute risk is extremely low, estimated at fewer than 20 cases per million patient-years, but the genital location means women may present differently than men. Seek immediate care for any genital pain, swelling, redness, or fever while on this drug.